Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Premature Ovarian Failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    60 result(s) found for: Premature Ovarian Failure. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2012-004511-30 Sponsor Protocol Number: POF01 Start Date*: 2013-01-16
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: A randomised controlled trial to compare the effect of micronized progesterone and Medroxyprogesterone Acetate on the vascular elasticity, lipid profile and coagulation cascade of women with premat...
    Medical condition: Premature ovarian failure.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002599-86 Sponsor Protocol Number: POF1 Start Date*: 2009-03-03
    Sponsor Name:Guy's and St Thomas Foundation NHS Trust [...]
    1. Guy's and St Thomas Foundation NHS Trust
    2. King's College London
    Full Title: A prospective open randomised controlled trial of women diagnosed with premature ovarian failure (POF) to investigate the effects of active treatment with HRT (hormone replacement therapy) or COCP ...
    Medical condition: Premature ovarian failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036602 Premature ovarian failure LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004400-19 Sponsor Protocol Number: 1707-FIVI-084-MV Start Date*: 2019-05-30
    Sponsor Name:IVIRMA MADRID
    Full Title: Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study.
    Medical condition: low ovarian reserve
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004532-10 Sponsor Protocol Number: POI-1 Start Date*: 2018-05-23
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of immunomodulatory therapy on gonadal function in women with autoimmune premature ovarian insufficiency
    Medical condition: Autoimmune premature ovarian insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10052660 Hypergonadotropic hypogonadism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000247-32 Sponsor Protocol Number: MAXINOVO Start Date*: 2020-11-03
    Sponsor Name:REPRODUCCION BILBAO (GINEGORAMA SL)
    Full Title: ACTIVATION OF PRIMORDIAL FOLLICULES AMONG WOMEN WITH POOR OVARIAN RESERVE BY USIN GROWTH FACTORS.
    Medical condition: The reproductive capacity of women depends on two factors: the number of follicles in the ovaries and the quality of oocytes within those follicles. Premature ovarian failure (POF) and poor ovaria...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005975-17 Sponsor Protocol Number: MO28113 Start Date*: 2012-08-17
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in ...
    Medical condition: Women with recurrent platinum-resistant or refractory epithelial ovarian cancer and low HER3 mRNA expression.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) IT (Completed) NL (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-002841-39 Sponsor Protocol Number: GINECO-OV-222 Start Date*: 2013-10-07
    Sponsor Name:ARCAGY GINECO
    Full Title: A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with rela...
    Medical condition: Patients with an histologically confirmed diagnosis of ovarian sex-cord stromal tumor in relapse after a platinum-based chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005717-40 Sponsor Protocol Number: 2001-FIVI-002-IC Start Date*: 2021-05-05
    Sponsor Name:IVI Foundation
    Full Title: Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman’s syndrome/ endometria atrophy)
    Medical condition: Endometrial pathologies (Thin endometrium/ Asherman's syndrome/ Endometrial atrophy)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001271-16 Sponsor Protocol Number: AGO-OVAR28 Start Date*: 2022-08-01
    Sponsor Name:AGO Research GmbH
    Full Title: Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)
    Medical condition: Patients with newly diagnosed, histologically confirmed, primary advanced invasive high grade epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer, FIGO stage III/IV (except FIGO ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003239-36 Sponsor Protocol Number: B9991010 Start Date*: 2016-08-22
    Sponsor Name:Pfizer Inc.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Unt...
    Medical condition: Epithelial ovarian cancer (EOC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) EE (Completed) IE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) DE (Completed) PL (Prematurely Ended) HR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005936-31 Sponsor Protocol Number: SMX18-001 Start Date*: 2021-05-24
    Sponsor Name:Sermonix Pharmaceuticals
    Full Title: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic E...
    Medical condition: Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001443-19 Sponsor Protocol Number: AC-058A200 Start Date*: 2008-11-26
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to su...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005166-12 Sponsor Protocol Number: HMPL-004-US-02 Start Date*: 2008-07-29
    Sponsor Name:Hutchison MediPharma Enterprises Limited
    Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine
    Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004362-34 Sponsor Protocol Number: A1481324 Start Date*: 2015-08-26
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) BE (Completed) DE (Completed) ES (Completed) CZ (Completed) RO (Completed) PL (Completed) GR (Completed) NL (Completed) PT (Completed) HR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004851-22 Sponsor Protocol Number: B7451015 Start Date*: Information not available in EudraCT
    Sponsor Name:Pfizer Inc., 66 Hudson Boulevard East, New York, NY 10001, U.S.A.
    Full Title: A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with m...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Trial now transitioned) PL (Trial now transitioned) NL (Ongoing) BG (Completed) BE (Completed) LV (Completed) ES (Ongoing) SK (Completed) FR (Completed) AT (Completed) SE (Prematurely Ended) IT (Completed) FI (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003866-14 Sponsor Protocol Number: B5091007 Start Date*: 2017-06-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
    Medical condition: Primary C difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-000918-38 Sponsor Protocol Number: C0311002 Start Date*: 2019-05-16
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROP...
    Medical condition: Growth Hormone Deficiency in Children
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-003372-37 Sponsor Protocol Number: ET11-072 Start Date*: 2014-06-04
    Sponsor Name:CENTRE LEON BERARD
    Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre...
    Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:23:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA